此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effects of Short and Long Courses of Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Including Elderly (EFIR)

A Single-Center Randomized Clinical Trial With Prospective Follow-up of the Efficacy and Safety of Short and Long Duration Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Mellitus Including Elderly Patients

This is a single-center randomized controlled trial evaluating the efficacy and safety of short (3 days) versus long (10 days) courses of intermittent hypoxic-hyperoxic training (IHHT) in patients with type 2 diabetes mellitus aged 50-74 years. Participants will be randomized into three groups: 3-day IHHT course (n≥100), 10-day IHHT course (n≥100), or control group receiving gas mixture with constant O2 21% for 10 days (n≥50). The primary outcomes are fasting glucose levels and HbA1c. Secondary outcomes include cardiovascular parameters, quality of life, cognitive function, and biological age.

研究概览

研究类型

介入性

注册 (估计的)

250

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Moscow、俄罗斯
        • 招聘中
        • National Medical Research Center for therapy and preventive medicine
        • 接触:
          • Oksana Drapkina
          • 电话号码:+7 (495) 212-07-13

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age 50-74 years inclusive
  • Type 2 diabetes mellitus confirmed by medical documentation
  • Stable therapy for diabetes and other chronic diseases for at least 4 weeks prior to enrollment
  • Ability to comply with study protocol requirements
  • Signed informed consent

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Acute diabetes complications within 6 months (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, hypoglycemic coma)
  • Acute or active chronic infections
  • Angina pectoris functional class III-IV
  • Uncontrolled grade 3 arterial hypertension (SBP ≥180 and/or DBP ≥110 mmHg)
  • Acute cerebrovascular accident, myocardial infarction, surgical interventions, clinically significant injuries within 6 months
  • Internal carotid artery stenosis >60% and/or symptomatic stenosis 50-99%
  • Chronic obstructive pulmonary disease and bronchial asthma
  • Exacerbation and decompensation of chronic diseases within 1 month ALT and/or AST levels >2-3 times upper limit of normal
  • Congenital heart and major vessel abnormalities
  • Implanted cardiac pacemaker
  • Cancer with remission <5 years
  • Mental illness, drug addiction, alcohol dependence
  • Pregnancy
  • Inability to participate throughout the study period

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm 1: Short Course IHHT (3 days)
Participants receive 3 consecutive daily sessions of IHHT (24 minutes each, 3 cycles of 5-min hypoxia/3-min hyperoxia, target SpO2 80-85%)
Three daily sessions using HYPO-OXY-1 (OXYTERRA) device
实验性的:Arm 2: Long Course IHHT (10 days)
Participants receive 10 daily sessions of IHHT (40 minutes each, 5 cycles of 5-min hypoxia/3-min hyperoxia, target SpO2 80-85%, excluding weekends and holidays)
Ten daily sessions using HYPO-OXY-1 (OXYTERRA) device
假比较器:Arm 3: Control
Participants receive 10 daily sessions of breathing gas mixture with constant O2 21% for 40 minutes (excluding weekends and holidays)
Ten daily sessions of breathing gas mixture with constant O2 21%

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in fasting glucose level (mmol/L) from baseline to 30±3 days after intervention completion
大体时间:Baseline, day 30
Fasting glucose will be measured after 8-12 hours of fasting using immunoturbidimetric method (Architect 8000C analyzer)
Baseline, day 30
Change in HbA1c (%) from baseline to 30±3 days after intervention completion
大体时间:Baseline, day 30
HbA1c will be measured using high-performance liquid chromatography (HPLC) on Lifotronic H8 analyzer
Baseline, day 30

次要结果测量

结果测量
措施说明
大体时间
Change in Cardio-Ankle Vascular Index (CAVI)
大体时间:Baseline, day 17-19, day 30
Baseline, day 17-19, day 30
Change in flow-mediated vasodilation (%)
大体时间:Baseline, day 17-19, day 30 post-intervention
Baseline, day 17-19, day 30 post-intervention
Change in 24-hour ambulatory blood pressure
大体时间:Baseline and 30±3 days post-intervention
Baseline and 30±3 days post-intervention
Change in quality of life by SF-36
大体时间:Baseline, day 17-19, and 30±3 days post-intervention
SF-36 is a 36-item patient-reported survey measuring health-related quality of life across 8 domains. Each domain is scored on a 0-100 scale, where higher scores indicate better quality of life.
Baseline, day 17-19, and 30±3 days post-intervention
Change in cognitive function by MoCA scale
大体时间:Baseline, day 17-19, and 30±3 days post-intervention
Montreal Cognitive Assessment scores range from 0-30, with scores ≥26 considered normal cognitive function
Baseline, day 17-19, and 30±3 days post-intervention
Change in anxiety and depression by HADS
大体时间:Baseline, day 17-19, and 30±3 days post-intervention
Hospital Anxiety and Depression Scale assesses anxiety and depression separately, each scored 0-21, with higher scores indicating greater symptom severity
Baseline, day 17-19, and 30±3 days post-intervention
Change in biological age
大体时间:Baseline and 30±3 days post-intervention
Baseline and 30±3 days post-intervention
Change in 6-minute walk test distance (meters)
大体时间:Baseline and 30±3 days post-intervention
Baseline and 30±3 days post-intervention

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Marina I Smirnova, PhD、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Svetlana A Berns, MD, Prof.、National Medical Research Center for therapy and preventive medicine
  • 首席研究员:Oksana M Drapkina, MD, Prof.、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Alexandr Yu Gorshkov, PhD、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Mikhail G Chashchin, PhD、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Liubov Lifanova, PhD、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Andrey I Korolev, PhD、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Diana N Antipushina, PhD、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Lidia N Ryuzhakova, PhD、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Elena N Ignatikova、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Svetlava Voinova、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Olga Zhdanova、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Ailina M Zhulaushinova、National Medical Research Center for therapy and preventive medicine
  • 学习椅:Alexandr V Emelyanov、National Medical Research Center for therapy and preventive medicine

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年10月15日

初级完成 (估计的)

2027年6月15日

研究完成 (估计的)

2027年12月15日

研究注册日期

首次提交

2026年2月21日

首先提交符合 QC 标准的

2026年5月4日

首次发布 (实际的)

2026年5月7日

研究记录更新

最后更新发布 (实际的)

2026年5月7日

上次提交的符合 QC 标准的更新

2026年5月4日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅